Sosei Group Corporation
Agreements physique connected Sosei Heptares’ Target Identification and Validation strategy and translational medicine attack to cause discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based cause design
TOKYO and CAMBRIDGE, United Kingdom, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the satellite person successful G protein-coupled receptor (GPCR) focused structure-based cause plan (SBDD) and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine astatine the University of Oxford, UK and KU Leuven, Belgium. The absorption of the agreements is to use the innovative technologies and probe capabilities of the respective world groups to identify, validate and prioritize cardinal GPCRs driving gastrointestinal and immune disorders, including inflammatory bowel illness (IBD), arsenic targets for SBDD.
IBD is simply a heterogenous chronic inflammatory illness with an expanding worldwide prevalence. Between 1990 and 2017, the fig of individuals with IBD accrued from implicit 3.5 cardinal to astir 7 million1. Despite the increasing therapeutic landscape, much than 50% of patients with IBD neglect to respond to accepted and precocious therapies. Primary reasons for therapeutic nonaccomplishment see the constricted knowing of the precise proteins, cells and mechanisms that alteration successful patients affected by this disease, arsenic good arsenic the poorly understood illness heterogeneity among patients.
Studies from the probe radical of Professor Alison Simmons astatine the MRC Human Immunology Unit, based successful the MRC Weatherall Institute of Molecular Medicine, volition use cutting-edge technologies successful operation with entree to quality diligent insubstantial samples to assistance uncover the relation of GPCRs driving chronic intestinal inflammation and supply caller opportunities for attraction successful IBD.
Research astatine KU Leuven, led by Professor Séverine Vermeire and Professor Bram Verstockt, provides a complementary multi-omic profiling approach, which volition interrogate highly curated patient samples to supply insights to the look and relation of GPCRs successful the IBD “interactome2”. Through this work, the partners expect to place and corroborate successful quality organoid cultures the biologic relevance of cardinal GPCR targets successful responding and non-responding diligent populations to assistance thrust further advances to marque precision medicine a world successful IBD.
Alastair Brown, SVP Translational Medicine astatine Sosei Heptares, said: “These agreements physique connected our committedness to excellence successful Translational Medicine and enactment our GPCR Target Identification and Validation strategy. This strategy sees america partnering with starring world probe institutions to heighten our translational medicine capabilities and accelerate the accidental to bring guardant caller GPCR targets for the attraction of gastrointestinal and immune disorders. Our partners, some successful Oxford and Leuven, bring important innovative and complementary skills that we judge volition assistance Sosei Heptares make a much informed knowing of the relation of GPCRs successful immune disorders and accelerate aboriginal cause find opportunities.”
Professor Alison Simmons, University of Oxford, added: “We are excited to beryllium moving with Sosei Heptares to harvester our respective probe capabilities to research the relation of cardinal gastrointestinal GPCRs whose enactment is altered successful inflammation. We purpose to trial our findings successful quality insubstantial samples and research however these could amended pass structure-based cause plan for caller therapeutics to beforehand intestinal wellness successful IBD.”
Professor Séverine Vermeire, KU Leuven added: “This statement with Sosei Heptares is grounds of the important involvement and imaginable interaction that improving our knowing of GPCRs whitethorn person connected aboriginal treatments for IBD. We are thrilled to participate into this R&D agreement, which provides an important nexus betwixt starring objective world centers and a clinical-stage biopharmaceutical institution pioneering GPCR-focused SBDD.”
Footnotes
1 GBD 2017 Inflammatory Bowel Disease Collaborators. The Lancet Gastroenterology and Hepatology. Volume 5, Issue 1, p17-30, January 01, 2020
2 The Interactome is a word referring to the entire acceptable of molecular interactions successful a peculiar cell.
About Sosei Heptares
We are an planetary biopharmaceutical radical focused connected the find and aboriginal improvement of caller medicines originating from our proprietary GPCR-targeted StaR® exertion and structure-based cause plan level capabilities. We are advancing a wide and heavy pipeline of caller medicines crossed aggregate therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.
We person established partnerships with immoderate of the world’s starring pharmaceutical companies and aggregate emerging exertion companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered successful Tokyo, Japan with firm and R&D facilities successful Cambridge, UK.
“Sosei Heptares” is the firm marque and trademark of Sosei Group Corporation, which is listed connected the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
For much information, delight sojourn https://www.soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco
Enquiries:
Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, Chief Financial Officer
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Candelle Chong, SVP Investor Relations and Corporate Strategy
Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 | IR@SoseiHeptares.com
MEDiSTRAVA Consulting (for International Media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com
English (US)